PARPi‐containing regimen vs non‐PARPi regimen
Grade ≥3 AEs · locally advanced or metastatic breast cancer
PARPi‐containing regimen showed no clear difference in grade ≥3 AEs compared with non‐PARPi regimen (moderate certainty).
1 finding from 1 review
- PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer 2021 · Cochrane Headline outcomes onlyRR 0.98 [0.91, 1.04]5 studies · 1443 participantsModerate